U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C25H22N2O2
Molecular Weight 382.4544
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GSK-650394

SMILES

OC(=O)C1=CC=C(C=C1C2CCCC2)C3=CNC4=NC=C(C=C34)C5=CC=CC=C5

InChI

InChIKey=WVSBGSNVCDAMCF-UHFFFAOYSA-N
InChI=1S/C25H22N2O2/c28-25(29)20-11-10-18(12-21(20)17-8-4-5-9-17)23-15-27-24-22(23)13-19(14-26-24)16-6-2-1-3-7-16/h1-3,6-7,10-15,17H,4-5,8-9H2,(H,26,27)(H,28,29)

HIDE SMILES / InChI

Molecular Formula C25H22N2O2
Molecular Weight 382.4544
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

GSK650394 was synthesized by the CVU Medicinal Chemistry Department at GlaxoSmithKline as an inhibitor of serum- and glucocorticoid-regulated kinases, SGK1 and SGK2. It was shown, that GSK650394 possessed antiproliferative properties against the human prostate carcinoma cell line LNCaP.

Originator

Curator's Comment: # CVU Medicinal Chemistry Department at GlaxoSmithKline

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: O00141|||Q5TCN4
Gene ID: 6446.0
Gene Symbol: SGK1
Target Organism: Homo sapiens (Human)
62.0 nM [IC50]
Target ID: Q9HBY8
Gene ID: 10110.0
Gene Symbol: SGK2
Target Organism: Homo sapiens (Human)
103.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Patents

Patents

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
The inhibitory effects of GSK650394 on SGK1 activity were evaluated using cell-based assays. Importantly, GSK650394 is relatively nontoxic, with LC50 values of 41 μmol/L in M-1 cells (68 times its activity IC50) and LC50 >100 μmol/L in HeLa cells in XTT assays, which measure mitochondrial enzymatic activity. GSK650394 was evaluated for its effects on this well-documented SGK1-mediated biological activity, which was measured using an aldosterone-stimulated SCC cellular assay. GSK650394 inhibited SGK1-mediated epithelial transport with an IC50 of 0.6 μmol/L in the SCC assay.
Substance Class Chemical
Created
by admin
on Sat Dec 16 09:49:13 GMT 2023
Edited
by admin
on Sat Dec 16 09:49:13 GMT 2023
Record UNII
56887611DJ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GSK-650394
Common Name English
BENZOIC ACID, 2-CYCLOPENTYL-4-(5-PHENYL-1H-PYRROLO(2,3-B)PYRIDIN-3-YL)-
Systematic Name English
Code System Code Type Description
PUBCHEM
25022668
Created by admin on Sat Dec 16 09:49:13 GMT 2023 , Edited by admin on Sat Dec 16 09:49:13 GMT 2023
PRIMARY
EPA CompTox
DTXSID60237532
Created by admin on Sat Dec 16 09:49:13 GMT 2023 , Edited by admin on Sat Dec 16 09:49:13 GMT 2023
PRIMARY
FDA UNII
56887611DJ
Created by admin on Sat Dec 16 09:49:13 GMT 2023 , Edited by admin on Sat Dec 16 09:49:13 GMT 2023
PRIMARY
CAS
890842-28-1
Created by admin on Sat Dec 16 09:49:13 GMT 2023 , Edited by admin on Sat Dec 16 09:49:13 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY